Clinical Trials Logo

Adenoid Cystic Carcinoma clinical trials

View clinical trials related to Adenoid Cystic Carcinoma.

Filter by:

NCT ID: NCT01558661 Completed - Clinical trials for Adenoid Cystic Carcinoma

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study. Axitinib is an oral medication that can interfere with cancer cell growth and reduce the growth of blood vessels around tumors. This study will help find out if axitinib is a useful drug for treating patients with adenoid cystic carcinomas. Axitinib is an experimental drug that has not yet been approved by the Food and Drug Administration for use in adenoid cystic carcinoma.

NCT ID: NCT01524692 Completed - Clinical trials for Adenoid Cystic Carcinoma

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

ACC
Start date: March 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to improve survival of patients with recurrent or metastatic Adenoid Cystic Carcinoma (ACC). This study will test the efficacy of the investigational drug, TKI258, in treating ACC.

NCT ID: NCT01417143 Completed - Clinical trials for Adenoid Cystic Carcinoma

Dovitinib in Adenoid Cystic Carcinoma

Start date: September 2011
Phase: Phase 2
Study type: Interventional

The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).

NCT ID: NCT01152840 Completed - Clinical trials for Adenoid Cystic Carcinoma

Study of RAD001 in Adenoid Cystic Carcinoma

ACCRAD001
Start date: July 2008
Phase: Phase 2
Study type: Interventional

- Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 has been systematically conducted in adenoid cystic carcinoma. - In phase I study of RAD001, 2 patients with adenoid cystic carcinoma show some response to RAD001 (unpublished data). - So the investigators design this phase II study of RAD001 in adenoid cystic carcinoma to evaluate the efficacy of RAD001 in this orphan disease.

NCT ID: NCT00886132 Completed - Clinical trials for Adenoid Cystic Carcinoma

A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland. There currently is not standard of care for this type of cancer and it has hoped that sunitinib will have antitumor effects on patients with this type of cancer.

NCT ID: NCT00581360 Completed - Clinical trials for Adenoid Cystic Carcinoma

Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

Start date: November 2007
Phase: Phase 2
Study type: Interventional

This is a Phase II trial non-randomized study to evaluate the objective response rate and stable disease rate (primary endpoints), progression-free survival, overall survival and toxicities with the combination of doxorubicin and bortezomib in patients with incurable head and neck adenoid cystic carcinoma. Also, we plan to collect tumor tissue from previous diagnostic procedures and baseline blood specimens for future correlative studies.